2011 - BSS 2011 Symposium


This page contains exclusive content for the member of the following sections: TTS. Log in to view.

Oral Presentations

4.1 - Heart and Kidney Cotransplantation in Non Human Primates (NHPs)

Presenter: Makoto, Tonsho, Boston, United States
Authors: Makoto Tonsho1, Svjetlan Boskovic1, Tatsuo Kawai1, Derek Klarin1, Ognjenka Nadazdin1, Robert B. Colvin2, Gilles Benichou1, A. Benedict Cosimi1, Joren C. Madsen1

Heart and Kidney Cotransplantation in Non Human Primates (NHPs)

Makoto Tonsho1, Svjetlan Boskovic1, Tatsuo Kawai1, Derek Klarin1, Ognjenka Nadazdin1, Robert B. Colvin2, Gilles Benichou1, A. Benedict Cosimi1, Joren C. Madsen1

1Transplant Center, Divisions of Cardiac Surgery and Abdominal Transplantation; 2Department of Pathology; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Background: The induction of immune tolerance would allow a heart allograft to survive long term without the need for dangerous immunosuppressive drugs. Tolerance has been achieved in NHP and human recipients of kidney transplants using a mixed chimerism approach. However, the same protocol could not induced tolerance in NHP recipients of heart allografts. We hypothesize that tolerance to cardiac allografts will be achieved when heart and kidney allografts from the same donor are cotransplanted.

Methods: Cynomolgus macaques were infused with allogeneic bone marrow cells and received either a heart alone or a combined heart/kidney transplant from the same donor. Prior to transplantation, recipients received a nonmyeloablative conditioning regimen consisting of two doses of 1.5 Gry total body irradiation (day -6, -5), one dose of 7 Gry thymic irradiation (day -1), three doses of 50 mg/kg equine anti-thymocyte globulin (day -2, -1, 0).  Starting at day 0, six doses of anti-CD154 monoclonal antibody and a 28-day course of cyclosporine were administered. Immune competence was monitored with ELISPOT, mixed lymphocyte reaction (MLR) and alloantibody production. Graft rejection was assessed by serial biopsies.

Result: Biopsies in three recipients of isolated heart allografts that developed transient multilineage chimerism demonstrated severe rejection as early as 69, 78, 82 days after transplantation despite survival to 489, 154 and 82 days. In contrast, the two combined heart and kidney recipients that developed transient multilineage chimerism demonstrated no evidence of acute rejection for over 260 days. In vitro studies in the longest heart/kidney survivor revealed that regulatory T cells were enriched from 5 % to 20 % of all CD4+ lymphocytes in periphery, and that gamma IFN-ELISPOT and MLR exhibited donor specific hyporesponsiveness despite detection of an alloantibody.

Conclusion: The tolerogenic effects of kidney allografts can be conferred upon cardiac allografts when the two organs are cotransplanted in recipients undergoing a mixed chimerism conditioning regimen. This effect may be related to the ability of the kidney, but not the heart, to transfer or expand regulatory T cells.

 

 


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada